News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chimerix, Inc. (CMRX)'s Brincidofovir (CMX001) Selected For Two Oral Presentations At The 2014 BMT Tandem Meetings


2/24/2014 9:00:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DURHAM, N.C., Feb. 21, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced two oral presentations related to its broad-spectrum investigational antiviral, brincidofovir (CMX001), at the BMT Tandem Meetings being held February 26 – March 2, 2014 in Grapevine, Texas. The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES